Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
22 October 2014Website:
http://www.protaratx.comNext earnings report:
13 March 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | 3 min agoDividend
Analysts recommendations
Institutional Ownership
TARA Latest News
NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer (NMIBC) will be featured during a poster session at the upcoming 25th Annual Meeting of the Society of Urologic Oncology (SUO) taking place December 4, 2024 to December 6, 2024, in Dallas, Texas. The presentation will include safety data featured in the abstract published today on the SUO website, as well as updated safety and new efficacy data from approximately 20 enrolled patients, the majority of whom are six-month evaluable.
NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference on Wednesday, November 13, 2024, at 2:00 pm ET in Boston.
NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the results of THRIVE-1, a prospective, observational study evaluating the prevalence of choline deficiency and liver injury in patients dependent on parenteral support (PS). Results from the study were featured during a poster session at the 46th European Society for Clinical Nutrition and Metabolism Congress (ESPEN), from September 7, 2024, to September 10, 2024, in Milan.
Protara Therapeutics (TARA) has shown a hammer chart pattern, suggesting that the stock has found support after a recent decline. This, along with an increase in earnings estimate revisions, may indicate a potential turnaround for the stock in the near future.
What type of business is Protara Therapeutics?
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.
What sector is Protara Therapeutics in?
Protara Therapeutics is in the Healthcare sector
What industry is Protara Therapeutics in?
Protara Therapeutics is in the Biotechnology industry
What country is Protara Therapeutics from?
Protara Therapeutics is headquartered in United States
When did Protara Therapeutics go public?
Protara Therapeutics initial public offering (IPO) was on 22 October 2014
What is Protara Therapeutics website?
https://www.protaratx.com
Is Protara Therapeutics in the S&P 500?
No, Protara Therapeutics is not included in the S&P 500 index
Is Protara Therapeutics in the NASDAQ 100?
No, Protara Therapeutics is not included in the NASDAQ 100 index
Is Protara Therapeutics in the Dow Jones?
No, Protara Therapeutics is not included in the Dow Jones index
When was Protara Therapeutics the previous earnings report?
No data
When does Protara Therapeutics earnings report?
The next expected earnings date for Protara Therapeutics is 13 March 2025